Topics

"TandemLife∨derfield=date∨derval=DESC" News Stories

14:06 EDT 18th July 2019 | BioPortfolio

Here are the most relevant search results for "TandemLife∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about TandemLife∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about TandemLife∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list TandemLife∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of TandemLife∨derfield=date∨derval=DESC Companies for you to search.

Showing "TandemLife derfield date derval DESC" News Articles 1–25 of 4,900+

Thursday 18th July 2019

UnitedCoatings Group Announces Acquisition of CoorsTek Medical

Acquisition Broadens UnitedCoatings’ Capabilities to Offer Comprehensive Supply Chain Solutions UnitedCoatings Group, together with its medical division (Eurocoating SpA, Surface Dynamics, NanoSurfaces Industries, Anteco and Eurocoating Medical Technology Wuxi), a leading global supplier of integrated contract manufacturing solutions to medical device OEMs, announced today that, after its acqu...


Phase II/III Study Trends and Market Outlook 2018-2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Phase II/III Study Trends and Market Outlook (2018-2022)” report has been added to ResearchAndMarkets.com’s offering. Keeping up-to-date with the evolving pharmaceutical market is no easy task. The constant flow of newsletters hitting our inboxes is almost too much … Continue reading →

Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents

Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that it was granted Patent No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate...


Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled for August 1, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast to report its second quarter 2019 update and financial results on Thursday, August 1 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (international) and reference the access code 2287274. The presentation will be available on the Investors section of w...

Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities

One of the nation’s largest hospital networks adopts vascular robotic technology in multiple hospital locations to treat patients in need of cardiovascular care Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has ins

Senseonics Announces Pricing of Public Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of 22,727,273 shares of its common stock at a price to the public of $1.10 per share. The gross proceed...

Senseonics Announces Pricing of $82.0 Million 5.25% Convertible Senior Notes Due 2025

Senseonics Holdings, Inc. (“Senseonics” or the “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of an $82.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 (the “2025 note...

Wednesday 17th July 2019

Potential benefits and risks of using e-cigarettes

While cigarette use for high school students is at an all-time low (8%), 21% of students in the United States report using e-cigarettes in the past month, which is the highest level to date.

Rising CO2, climate change projected to reduce availability of nutrients worldwide

(International Food Policy Research Institute) The most comprehensive synthesis of climate change impacts on the global availability of nutrients to date finds that, over the next 30 years, climate change and higher CO2 could significantly reduce the availability of critical nutrients, representing another challenge to global development and the fight to end undernutrition.

5 Top NASDAQ Biotech Stocks Year-to-Date

The first half of 2019 is done, which means it's time to look back on the top performing NASDAQ biotech stocks year-to-date. The post 5 Top NASDAQ Biotech Stocks Year-to-Date appeared first on Investing News Network.

Agilent Technologies, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 11032019] Prices from USD $175

Agilent Technologies, Inc. Strategy, SWOT and Corporate Finance ReportSummaryAgilent Technologies, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsAgilent Technologi...

Sesen Bio Announces Retirement of Leslie L. Dan

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Leslie L. Dan has retired from the Company's Board of Directors, effective July 16, 2019. With the retirement of Mr. Dan, the Company’s Board of Directors will be comprised of five directors of which four are independent. The Com...

Human medicines European public assessment report (EPAR): Ikervis, ciclosporin, Corneal Diseases, Date of authorisation: 19/03/2015, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ikervis, ciclosporin, Corneal Diseases, Date of authorisation: 19/03/2015, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Xultophy, insulin degludec / liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 18/09/2014, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Xultophy, insulin degludec / liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 18/09/2014, Revision: 12, Status: Authorised

On this date in 1919, Nature reported how women were again barred from the engineering field following WWI. “There is no doubt that many women developed great mechanical skill and a real love of their work.” https://go.nature.com/2JE0udr 

On this date in 1919, Nature reported how women were again barred from the engineering field following WWI. “There is no doubt that many women developed great mechanical skill and a real love of their work.” https://go.nature.com/2JE0udr 

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz / emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 08/02/2018, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz / emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 08/02/2018, Revision: 3, Status: Authorised

Giant Food Stores shares 2nd Giant Heirloom Market opening date

Applied DNA Raises $1.5 Million In Secured Convertible Notes

Existing Notes Amended as Part of Plan to Strengthen Balance Sheet and Regain Nasdaq Listing Standards Compliance Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufacturing for product authenticit

Achieve TMS and Progeny Psychiatric Group to Host July 22 Open House at New Irvine Center

The free event will allow the general public and mental health practitioners to learn more about Achieve TMS, Progeny Psychiatric Services and deep transcranial magnetic stimulation (dTMS) for treating depression. IRVINE, Calif. (PRWEB) July 17, 2019 Achieve TMS, a leading provider of Deep Transcranial Magnetic Stimulation (dTMS) treatment for people who suffer from depression, will celebrate the...

Rebate rules, IPI, and importation — oh my! If you're also struggling to keep track of everything Congress and Trump are talking about on drug pricing, never fear — @NicholasFlorko and @levfacher have an easy-to-read tracker that'll keep you up to d

Rebate rules, IPI, and importation — oh my! If you're also struggling to keep track of everything Congress and Trump are talking about on drug pricing, never fear — @NicholasFlorko and @levfacher have an easy-to-read tracker that'll keep you up to date: https://www.statnews.com/feature/drug-pricing/policy-tracker/ …

ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019

ACADIA to Host Conference Call and Webcast on Wednesday, July 31, 2019, at 4:30 p.m. Eastern Time ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter end...

Know Labs Announces Significant Pre-Clinical Progress of UBAND Non-Invasive Continuous Glucose Monitor

Know Labs, Inc. (OTCQB: KNWN) – a creator of innovative medical diagnostic solutions, today announced significant progress in the development of its wearable UBAND non-invasive Continuous Glucose Monitor (CGM). Increased accuracy and precision in laboratory test subject measurements have allowed the Company to expedite its focus on an FDA-approved CGM, causing it to curtail plans for its previo...

Myomo®'s International Distribution Partners Launch Patient Screening Days

Over 50 screening days planned in six countries Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces that its international distributors in six countries are adopting the marketing model used successfully in the U.S. of introd...

Cresco Labs Hires Angie Demchenko as its First Chief People Officer

Cresco Labs Inc. (“Cresco Labs” or the “Company”) (CSE: CL) (OTCQX: CRLBF), one of the largest vertically integrated multistate cannabis operators in the United States, today announced that Angie Demchenko has joined the Company as its first Chief People Officer. Ms. Demchenko most recently served as Vice President, Head of Human Resources for Starwood Retail Partners, a leading operator ...

Human medicines European public assessment report (EPAR): Maviret, glecaprevir / pibrentasvir, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Maviret, glecaprevir / pibrentasvir, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 6, Status: Authorised


Quick Search

News Quicklinks